Cytek Biosciences Inc - Asset Resilience Ratio
Cytek Biosciences Inc (CTKB) has an Asset Resilience Ratio of 36.98% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Cytek Biosciences Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Cytek Biosciences Inc's Asset Resilience Ratio has changed over time. See Cytek Biosciences Inc book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Cytek Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CTKB market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $170.68 Million | 36.98% |
| Total Liquid Assets | $170.68 Million | 36.98% |
Asset Resilience Insights
- Very High Liquidity: Cytek Biosciences Inc maintains exceptional liquid asset reserves at 36.98% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cytek Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Cytek Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 3.37% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS |
Medical Devices | 54.67% |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO |
Medical Devices | 30.97% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
|
Aligned Genetics Inc
KQ:238120 |
Medical Devices | 2.22% |
|
Heramed Ltd
AU:HMD |
Medical Devices | 0.83% |
|
Acarix A/S
ST:ACARIX |
Medical Devices | 37.81% |
Annual Asset Resilience Ratio for Cytek Biosciences Inc (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Cytek Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 36.98% | $170.68 Million | $461.54 Million | +1.11pp |
| 2024-12-31 | 35.86% | $179.15 Million | $499.50 Million | +16.63pp |
| 2023-12-31 | 19.24% | $95.11 Million | $494.46 Million | +10.66pp |
| 2022-12-31 | 8.58% | $44.55 Million | $519.48 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $463.31 Million | -- |
About Cytek Biosciences Inc
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more